Compare AbCellera Biologics Inc (ABCL) vs Global X Cloud Computing ETF (CLOU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

CLOU trades at $23.43, up 0.9% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to the cloud computing sector, though key valuation and profitability metrics are not disclosed in the provided data. Recent news highlights mixed performance for cloud ETFs, with some articles discussing growth potential from AI platforms while others note significant past losses in similar funds.

The outlook for CLOU hinges on broader technology and cloud computing trends, with AI adoption presenting a potential catalyst. Risks include sector volatility, competitive pressures, and regulatory developments, as seen in Europe's push for tech sovereignty. Investors should weigh the ETF's diversification benefits against the inherent uncertainties in the tech landscape.